Literature DB >> 748373

Properties of endogenous somatostatin-like immunoreactivity and synthetic somatostatin in dog plasma.

J M Conlon, C B Srikant, E Ipp, V Schusdziarra, W Vale, R H Unger.   

Abstract

Somatostatin-like immunoreactivity (SLI) in the peripheral venous plasma of dogs and in their pancreatic and gastric venous effluents was characterized and compared with synthetic somatostatin. Both endogenuous plasma SLI and somatostatin added to plasma were eluted from Sephadex gels at pH 8.8 in the 150,000--200,000-mol wt region but at pH 2.5 both appeared in the 1,500--2,000-mol wt region. The SLI released from the isolated dog pancreas perfused with plasma-free buffer was eluted entirely as a 1,600-dalton polypeptide, but when the pancreas was perfused with plasma, SLI was eluted in the 150,000--200,000-mol wt zone. Affinity chromatography of plasma samples on immobilized antibodies directed against the central portion of the somatostatin molecule (residues 5--9 and 11) removed approximately equal to 90% of both endogenous SLI and somatostatin added to plasma, but neither was removed by affinity chromatography on antibodies directed against the NH2-terminal region of somatostatin (residues 1--4). The SLI from plasma and from pancreas perfusate isolated by affinity chromatography was identical in molecular size, charge, and immunometric properties to synthetic somatostatin. It is concluded that endogenous SLI is secreted by the pancreas and stomach in a form not distinguishable from synthetic somatostatin, but circulates in plasma bound to large molecular weight components; the NH2-terminal residues of somatostatin appear to be important in this binding.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 748373      PMCID: PMC371883          DOI: 10.1172/JCI109238

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Biologic and immunologic activities and applications of somatostatin analogs.

Authors:  W Vale; J Rivier; N Ling; M Brown
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

2.  Comparison of non-biospecific effects in immunoaffinity chromatography using cyanogen bromide and bifunctional oxirane as immobilising agents.

Authors:  R F Murphy; J M Conlon; A Imam; G J Kelly
Journal:  J Chromatogr       Date:  1977-05-21

3.  Properties of soluble somatostatin-binding protein.

Authors:  N Ogawa; T Thompson; H G Friesen; J B Martin; P Brazeau
Journal:  Biochem J       Date:  1977-08-01       Impact factor: 3.857

4.  The characterization of somatostatin-like immunoreactivity in human serum.

Authors:  S Kronheim; M Berelowitz; B L Pimstone
Journal:  Diabetes       Date:  1978-05       Impact factor: 9.461

5.  Somatostatin-like immunoreactivity (SRIF-LI) in human and rat serum.

Authors:  B Primstone; M Berelowitz; D Kranold; B Shapiro; S Kronheim
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

6.  Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat.

Authors:  Y C Patel; S Reichlin
Journal:  Endocrinology       Date:  1978-02       Impact factor: 4.736

7.  Pancreatic immunoreactive somatostatin release.

Authors:  G S Patton; E Ipp; R E Dobbs; L Orci; W Vale; R H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

8.  Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog.

Authors:  V Schusdziarra; V Harris; J M Conlon; A Arimura; R Unger
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

9.  Properties of immunoreactive glucagon fractions of canine stomach and pancreas.

Authors:  C B Srikant; K McCorkle; R H Unger
Journal:  J Biol Chem       Date:  1977-03-25       Impact factor: 5.157

10.  Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.

Authors:  E Ipp; R E Dobbs; A Arimura; W Vale; V Harris; R H Unger
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

View more
  10 in total

1.  Muscle cell electrical hyperpolarization and reduced exercise hyperkalemia in physically conditioned dogs.

Authors:  J P Knochel; J D Blachley; J H Johnson; N W Carter
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 2.  Multiple forms of gastroenteropancreatic hormones.

Authors:  G B Irvine; R F Murphy
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

3.  Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog.

Authors:  K S Polonsky; J B Jaspan; M Berelowitz; D S Emmanouel; J Dhorajiwala
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

4.  Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs.

Authors:  T Wasada; B Howard; R E Dobbs; R H Unger
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

5.  Clearance of immunoreactive somatostatin by perfused rat liver.

Authors:  H Sacks; L C Terry
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

Review 6.  Secretion of somatostatin from the normal and diabetic pancreas. Studies in vitro.

Authors:  K Hermansen
Journal:  Diabetologia       Date:  1980       Impact factor: 10.122

7.  Determination of immunoreactive somatostatin in rat plasma and responses to arginine, glucose and glucagon infusion.

Authors:  M Utsumi; H Makimura; K Ishihara; S Morita; S Baba
Journal:  Diabetologia       Date:  1979-11       Impact factor: 10.122

8.  Plasma somatostatin-like immunoreactivity during the interdigestive period in the dog.

Authors:  I Aizawa; Z Itoh; V Harris; R H Unger
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

9.  The effects of the antimuscarinic drugs pirenzepine and atropine on plasma portal levels of somatostatin and gastrin in the dog.

Authors:  M Del Tacca; G Soldani; A Polloni; C Bernardini; F Costa; M Bellini
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

10.  Measurement, characterization, and source of somatostatin-like immunoreactivity in human amniotic fluid.

Authors:  D Fitz-Patrick; Y C Patel
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.